Article Text


A10.24 Switching Infliximab for New Alternatives: A Correspondence Analysis of Biologics, Reasons to Stop, and Time Periods
  1. Julia Uceda1,
  2. Loreto Carmona2,
  3. Alejandro Muñoz1,
  4. Jose L Marenco1
  1. 1Rheumatology Department, Valme University Hospital, Sevilla, Spain
  2. 2Camilo José Cela University, Madrid, Spain


Background The reason to stop the first biologic may vary from agent to agent and also from the earlier times to the more recent ones. Issues like the availability of newer alternatives or a better knowledge of the effectiveness and safety profile of individual biologics may influence treatment decisions, including the discontinuation of the biologic.

Objective To visually assess the relationship between the reason for stopping the first biologic and the period of time when the biologic was started.

Methods All patients with rheumatoid arthritis undergoing treatment with a biologic are registered in the clinical database of a single centre with seven treating rheumatologists. The biologic used, as well as the reason to stop it is recorded, as well as all dates regarding the start and the last dose. We performed a multiple correspondence analysis with the Burt method of adjusted inertias and standard normalisation with the variables: first biologic, time period (1998–2001, 2002–2005, 2006–2009), and reason to stop (adverse event, inefficacy, others). Correspondence analysis provides a means of displaying or summarising a set of data with categorical variables in two-dimensional graphical form.

Results The total inertia of the exploratory analysis was 0.10. The first two dimensions added to 57% of the inertia, so that all dimensions were accounted for. The major drives of the relationship between the three variables were “infliximab” and the time period “1998–2001” (% inertia 0.146 and 0.177, respectively). The distance between other categories of the three variables was not relevant enough to make any suggestions of an association. The figure shows the correspondence map of the relationship.

Conclusions If to any biologic at all, time has affected the decision to start infliximab, with more treatments started in the earlier times than in the later ones. The reason to stop any first biologic does not clearly relate to the time neither to the biologic itself in this single centre dataset.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.